Seroatlas · Human Serome Atlas

PRSS50

Probable threonine protease PRSS50

Also known as: CT20, TSP50, TSP50_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UI38
Gene: PRSS50
Ensembl: ENSG00000283706
Chromosome: 3
Canonical length: 385 aa
Protein class: Enzymes, Predicted intracellular proteins
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Enables threonine-type endopeptidase activity. Involved in proteolysis. Located in endoplasmic reticulum. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

385 residues, UniProt reviewed canonical sequence.

>Q9UI38|PRSS50
     1  MGRWCQTVAR GQRPRTSAPS RAGALLLLLL LLRSAGCWGA GEAPGALSTA DPADQSVQCV
    61  PKATCPSSRP RLLWQTPTTQ TLPSTTMETQ FPVSEGKVDP YRSCGFSYEQ DPTLRDPEAV
   121  ARRWPWMVSV RANGTHICAG TIIASQWVLT VAHCLIWRDV IYSVRVGSPW IDQMTQTASD
   181  VPVLQVIMHS RYRAQRFWSW VGQANDIGLL KLKQELKYSN YVRPICLPGT DYVLKDHSRC
   241  TVTGWGLSKA DGMWPQFRTI QEKEVIILNN KECDNFYHNF TKIPTLVQII KSQMMCAEDT
   301  HREKFCYELT GEPLVCSMEG TWYLVGLVSW GAGCQKSEAP PIYLQVSSYQ HWIWDCLNGQ
   361  ALALPAPSRT LLLALPLPLS LLAAL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRSS50 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 51 nTPM

Expression across tissuesHPA

Tissue

testis: 51 nTPM
pituitary gland: 18 nTPM
thyroid gland: 17 nTPM
kidney: 5.8 nTPM
cervix: 4.9 nTPM
prostate: 4.8 nTPM

Single-cell type

astrocytes: 1.9 nCPM
choroid plexus epithelial cells: 1.3 nCPM
bergmann glia: 1.2 nCPM
other brain neurons: 1.1 nCPM
ependymal cells: 0.4 nCPM
brain excitatory neurons: 0.3 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 4 nTPM
medulla oblongata: 2.2 nTPM
spinal cord: 2.1 nTPM
hypothalamus: 2 nTPM
cerebral cortex: 1.7 nTPM
hippocampal formation: 1.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PRSS50.

Disease | ImmuneIEDB

Conditions an epitope on PRSS50 was assayed in.

colon adenocarcinoma T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.99
gnomAD pLI: 0
gnomAD missense Z: 0.66
DepMap mean gene effect: -0.15
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

proteolysis

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRSS50 as an antibody target. Whether an autoantibody or antibody against PRSS50 could matter depends on whether native PRSS50 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRSS50 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRSS50 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...